Gibson recently wrapped filming on his long-awaited sequels, which he's described as "an acid trip." ...
Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...
A late clinical-stage cardiovascular biotech focused on hypertrophic cardiomyopathy (HCM). The company is advancing a selective cardiac myosin inhibitor toward global Phase III development as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results